Bone turnover markers
After 12 months of the study drug, patients receiving alendronate had a significant reduction in serum CTX compared to baseline (0.32 ± 0.22 vs 0.57 ± 0.52 ng/ml, p = 0.002) (Changes in bone turnover markers; 